Alvotech And STADA Extend Partnership Through AVT03 Biosimilar Candidate Addition
Portfolio Pulse from Benzinga Newsdesk
Alvotech and STADA have extended their partnership to include the AVT03 biosimilar candidate. Alvotech will handle development and manufacturing, while STADA will manage marketing and commercial rights in Europe, Central Asia, and the Middle East.
June 11, 2024 | 8:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alvotech has extended its partnership with STADA to include the AVT03 biosimilar candidate. Alvotech will be responsible for development and manufacturing, potentially boosting its production capabilities and market presence.
The extension of the partnership with STADA to include the AVT03 biosimilar candidate is likely to positively impact Alvotech by enhancing its production capabilities and market presence. This could lead to increased revenues and a stronger market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80